Search
Displaying 151–160 of 573 for “Retinitis pigmentosa”
-
Persevering to Success with the Support of Family, Friends, and Faith
Beacon StoriesA story about living with retinitis pigmentosa.
-
French Gene Therapy Company Advancing Three Programs for Retinal Diseases
Research NewsHorama’s gene therapies are injections of healthy copies of a gene underneath the retina to compensate for the defective gene.
-
Study Suggests Vitamin A May Benefit Children with RP
Research NewsAn FFB-funded study at Massachusetts Eye andEar Infirmary (MEEI) suggests that vitamin A palmitate supplementation may slow the decline of cone function by nearly 50 percent in children with retinitis pigmentosa (RP).
-
AGTC Launches XLRP Gene Therapy Clinical Trial at Five Sites in U.S.
Research NewsTaking place at five locations in the United States, the clinical trial will enroll approximately 15 males with X-linked retinitis pigmentosa caused by mutations in the gene RPGR and will primarily evaluate safety.
-
Disease
Often diagnosed in childhood or adolescence, Usher syndrome is an inherited disease causing combined hearing loss and vision loss from retinitis pigmentosa. The condition can also cause problems with balance.
-
Disease
Often diagnosed in childhood or adolescence, BBS is an inherited disease causing progressive loss of night and peripheral vision from retinitis pigmentosa. BBS can also cause a number of other symptoms and problems including: obesity, extra fingers and toes, kidney disease, and developmental disabilities. Symptoms vary from person to person.
-
The Foundation's Investments Are Filling the Pipeline for Vision-Saving Therapies
Research NewsIn addition to funding promising biotech start-ups, the Foundation Fighting Blindness has played a critical role in developing research talent.
-
FFB-Funded Scientists Report on Nine Promising Translational Research Efforts
Research NewsThe Foundation Fighting Blindness has taken the translational challenge head on by investing more than $75 million in therapy-development projects with strong clinical-trial potential through its Translational Research Acceleration Program (TRAP), which includes Gund-Harrington Scholar Awards.
-
Researchers Find Mutation as Frequent Cause of RP in American Hispanics
Research NewsThe discovery can help genetic experts diagnose more patients with adRP, and it gives researchers a target for developing potential therapies.
-
Valproic Acid's Effect Too Small in One-Year Clinical Trial
Research NewsWhile a therapy for adRP will not emerge from the clinical trial, study investigators advanced development of a new outcome measure known as EZ Area to quickly and accurately evaluate potential therapies for RP in human studies.
